Therapeutic Specialties Archives

Case Study

Galderma Achieves FDA Approval of AKLIEF® (trifarotene)

In October 2019, Galderma announced that the U.S. FDA approved AKLIEF® (trifarotene) Cream, 0.005% for the…

CertaraNovember 9, 2020

White Paper

The Effects of COVID-19 on Stakeholder Engagement & Value Communication: Preparing for the New Normal

CertaraOctober 28, 2020

Publication

Clinical trials of disease stages in COVID 19: complicated and often misinterpreted

As of July 28, 2020, 1840 clinical trials were registered globally, with 1001 clinical trials…

CertaraAugust 22, 2020

Publication

Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19

As the global COVID-19 pandemic continues, unabated and clinical trials demonstrate limited effective pharmaceutical interventions,…

CertaraAugust 22, 2020

Publication

Quantitative Systems Pharmacology approaches for immuno‐oncology: adding virtual patients to the development paradigm

Drug development in oncology commonly exploits the tools of molecular biology to gain therapeutic benefit…

CertaraJuly 26, 2020

Blog

The Research to Accelerate Cures and Equity (RACE) for Children Act: Changing the Landscape of Pediatric Cancer Drug Development

3 key tips to set your pediatric program up for success with the RACE for…

CertaraJuly 14, 2020

Publication

Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology

Bispecific antibodies (bsAbs) have become an integral component of the therapeutic research strategy to treat…

CertaraJuly 14, 2020

Blog

Local Therapies for the Global COVID-19 Pandemic

Henri Merdjan explains why topical drug formulations (e.g. intranasal and/or oral) could be valuable as…

CertaraMay 29, 2020

Blog

Applying decision analysis to drug development for COVID-19 & future pandemics

This blog discusses how decision analysis approaches can help drug developers to better decisions under…

CertaraApril 30, 2020

On-Demand Webinar

The Rare Disease Drug Dilemma: Great Value, High Price, Limited Access?

This webinar will explain how pricing has evolved for the rare disease drug market and…

CertaraFebruary 19, 2020

Therapeutic Specialties

Galderma Achieves FDA Approval of AKLIEF® (trifarotene)

The Effects of COVID-19 on Stakeholder Engagement & Value Communication: Preparing for the New Normal

Clinical trials of disease stages in COVID 19: complicated and often misinterpreted

Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19

Quantitative Systems Pharmacology approaches for immuno‐oncology: adding virtual patients to the development paradigm

The Research to Accelerate Cures and Equity (RACE) for Children Act: Changing the Landscape of Pediatric Cancer Drug Development

Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology

Local Therapies for the Global COVID-19 Pandemic

Applying decision analysis to drug development for COVID-19 & future pandemics

The Rare Disease Drug Dilemma: Great Value, High Price, Limited Access?

Newsletter sign up

Quick links

Solutions

Contact